drugset / Trial / NCT00733551

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.

NCT00733551

Phase 1 Completed 31 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses of GSK962040.

Timeline

Start
2008-09-23
Primary completion
2009-07-20
Completion
2009-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject camicinal Small molecule 10 mg Oral
Subject camicinal Small molecule 30 mg Oral
Subject camicinal Small molecule 100 mg Oral

Indications